ライフサイエンスコーパス: platelet-activating factor

1 ulation of a G-protein coupled receptor with platelet activating factor.

2 significantly inhibited the biosynthesis of platelet activating factor.

3 ripeptides and possibly leukotriene B(4) and platelet activating factor.

4 hingomyelin (SM) to ceramide and inactivates platelet activating factor.

5 y alcohols, which are possible precursors of platelet activating factor.

6 trates for the production of eicosanoids and platelet-activating factor.

7 -containing lipids, such as lyso-PC, PC, and platelet-activating factor.

8 2-AG) are unaffected by LPS but increased by platelet-activating factor.

9 human epithelial cells via the receptor for platelet-activating factor.

10 ector cells, and the mediators histamine and platelet-activating factor.

11 ins in whole blood and dampened responses to platelet-activating factor.

12 ed priming of this response by TNF-alpha and platelet-activating factor.

13 is induced by administration of histamine or platelet-activating factor.

14 rmation was also reversed by the addition of platelet-activating factor.

15 owing to elevated levels of pro-inflammatory platelet-activating factors.

16 Platelet-activating factor (1-alkyl-2-acetyl-3-glyceroph

17 Platelet-activating factor (1-O-alkyl-2-acetyl-sn-glycer

18 els for 1 hour and intraluminal injection of platelet activating factor (50 micro/kg).

19 that were 50-70% of those induced by 100 nM platelet-activating factor, a positive control.

20 toxic injury via activation of receptors for platelet-activating factor, a proinflammatory signaling

21 tic oxidatively truncated phospholipids, and platelet-activating factor, a remarkably potent and plei

22 Low platelet activating factor acetyl hydrolase activity was

23 oluble tumor necrosis factor receptor I, and platelet activating factor acetyl hydrolase.

24 with the HDL-associated enzymes paraoxonase, platelet activating factor acetylhydrolase (PAF), and gl

25 nts, the most potent effect was observed for platelet activating factor acetylhydrolase alpha (Paf-AH

26 gulation of expression of the plasma form of platelet-activating factor acetylhydrolase (PAF AH) in t

27 Platelet-activating factor acetylhydrolase (PAF-AH) is a

28 The enzyme platelet-activating factor acetylhydrolase (PAF-AH) rapi

29 or was inactivated by alkaline hydrolysis or platelet-activating factor acetylhydrolase (PAF-AH) trea

30 the possibility that the activity represents platelet-activating factor acetylhydrolase (PAF-AH), an

31 We report that platelet-activating factor acetylhydrolase (PAFAH) Ib, c

32 t that the cytoplasmic PLA(2) enzyme complex platelet-activating factor acetylhydrolase (PAFAH) Ib, w

33 fective milk containing diminished levels of platelet-activating factor acetylhydrolase (PAFAH).

34 Platelet-activating factor acetylhydrolase (PLA2G7) is a

35 Platelet-activating factor acetylhydrolase 1B1 (LIS1), a

36 lycopene), and antioxidant enzyme activity (platelet-activating factor acetylhydrolase [PAF-AH] and

37 A recent report demonstrates that plasma platelet-activating factor acetylhydrolase activity incr

38 om allergy, such as suggesting that baseline platelet-activating factor acetylhydrolase activity leve

39 ll dense low-density lipoproteins, increased platelet-activating factor acetylhydrolase activity, and

40 Plasma platelet-activating factor acetylhydrolase becomes progr

41 lesterolemic human plasma with a recombinant platelet-activating factor acetylhydrolase completely ab

42 izygous mutations in the human gene encoding platelet-activating factor acetylhydrolase IB subunit al

43 The activities of paraoxonase and platelet-activating factor acetylhydrolase in HDL decrea

44 imal study, transfection of tumor cells with platelet-activating factor acetylhydrolase inhibited tum

45 nt controversy over whether paraoxonase 1 or platelet-activating factor acetylhydrolase is responsibl

46 rpose of this study was to determine whether platelet-activating factor acetylhydrolase Sse and strep

47 creened by enzymatic assays for SpeB and the platelet-activating factor acetylhydrolase Sse, and a ne

48 of lipoprotein-associated phospholipase A2 (platelet-activating factor acetylhydrolase), the express

49 coding complement component receptor 2/CD21, platelet-activating factor acetylhydrolase, and oxidized

50 tions in the relative levels of paraoxonase, platelet-activating factor acetylhydrolase, ceruloplasmi

51 n-associated phospholipase A2, also known as platelet-activating factor acetylhydrolase, is a new ris

52 lation and elongation protein zeta-1 (FEZ1), platelet-activating factor acetylhydrolase, isoform Ib,

53 e inconclusive in determining whether plasma platelet-activating factor acetylhydrolase, or lipoprote

54 nzymes, BChE and a new extracellular form of platelet-activating factor acetylhydrolase, PAFAH1b2.

55 ated phospholipase A2 (Lp-PLA2), also called platelet-activating factor acetylhydrolase, plays in ath

56 Lp-PLA2, also known as platelet-activating factor acetylhydrolase, rapidly clea

57 hospholipase A(2) (Lp-PLA(2)), also known as platelet-activating factor acetylhydrolase.

58 ted protein and as one subunit of the enzyme platelet-activating factor acetylhydrolase.

59 Platelet-activating factor acetylhydrolases (PAF-AHs) ar

60 Finally, Tat and platelet-activating factor also increased neuronal vesic

61 ory cellular metabolite up-regulated by Tat, platelet-activating factor, also induced oxidative stres

62 We report that platelet-activating factor, an inflammatory phospholipid

63 In hippocampal slices exposed to a stable platelet-activating factor analogue, tetanic stimulation

64 mesangial cell line induced upregulation of platelet activating factor and the fibrotic marker TGF-b

65 As platelet-activating factor and HPC share structural semb

66 on anaphylaxis suggest an important role for platelet-activating factor and its relationship to the n

67 flammatory mediators (tumor necrosis factor, platelet-activating factor and prostaglandins), studies

68 These mediators include platelet-activating factor and the eicosanoids, includin

69 ng receptors for chemokines, PGs, histamine, platelet activating factor, and anaphylatoxin.

70 ith N-formyl-methionyl-leucyl-phenylalanine, platelet activating factor, and leukotriene B4 was phosp

71 ory G protein-coupled chemoattractants fMLP, platelet-activating factor, and IL-8 elicit unique patte

72 Lysophosphatidylcholine, lyso-platelet-activating factor, and several phospholipid fat

73 production induced by TNF-alpha, GM-CSF, and platelet-activating factor, and this loss of pyk2 activi

74 locked by a combination of antihistamine and platelet-activating factor antagonist (but neither alone

75 e mediated by the autocrine activity, not of platelet-activating factor, but rather of endogenous CCR

76 d to surrogate PMNs respond to activation by platelet activating factor by initiating translation and

77 Tsujimura et al. report that the release of platelet-activating factor by basophils stimulated with

78 uding vascular endothelial growth factor and platelet-activating factor; by contrast, endothelial cel

79 d immunoglobulins (IgG, IgA), cytokines with platelet activating factor, calcium ionophore, or phorbo

80 irway eosinophils to chemoattractants (FMLP, platelet-activating factor, CCL11, CCL5, CXCL8) with res

81 se in cytosolic Ca2+ whereas the addition of platelet-activating factor did.

82 as prior exposure to a p38-activating agent (platelet-activating factor) diminished the TNFalpha-indu

83 cellular calcium concentration stimulated by platelet-activating factor, fMLP, and SP-G.

84 some of these peptides (eg, endothelin-1 and platelet-activating factor) has decreased mortality and

85 when elicited by leukotriene B4, C5a, FMLP, platelet-activating factor, IL-8, or RANTES chemotactic

86 surfactant phospholipids and biosynthesis of platelet-activating factor in noninflammatory remodeling

87 -third, suggesting a role for toxin-produced platelet-activating factor in this process.

88 via CD14-, NF-kappaB-, and p44/42-dependent, platelet-activating factor-independent activation of the

89 ogen synthase kinase 3beta inhibitor, blocks platelet activating factor-induced activation of glycoge

90 otected primary astrocytes from H(2)O(2)- or platelet-activating factor-induced apoptosis.

91 In ADSA lymphoblasts, platelet-activating factor-induced Ca(2+) mobilization w

92 ependent manner, LXs significantly inhibited platelet-activating factor-induced increases in leukocyt

93 Following platelet-activating factor-induced shock, MK886 increase

94 NET formation after stimulation with platelet activating factor, ionomycin, or phorbol 12-myr

95 Using our model, we also show that platelet-activating factor is a crucial mediator of both

96 duction of prostaglandins, leukotrienes, and platelet-activating factor, is present in EAE lesions.

97 ional studies demonstrated that RGS1 impairs platelet activating factor-mediated increases in intrace

98 gosine blocks thapsigargin-, ionomycin-, and platelet-activating factor-mediated SOCE despite normal

99 ceptor antagonists, or overexpression of the platelet-activating factor metabolizing enzyme acetylhyd

100 depletion by the G protein-coupled agonists platelet-activating factor or fMLP, but abolished agonis

101 tional state, and subsequent activation with platelet-activating factor or formyl-methionyl-leucyl-ph

102 Furthermore, platelet-activating factor or interleukin 8 acted in con

103 ormally sensitive to substance P, but not to platelet-activating factor or serotonin, suggesting that

104 merous chemoattractants, such as chemokines, platelet-activating factor, or FMLP, through a process k

105 ls with G protein-coupled receptor agonists, platelet-activating factor, or FMLP.

106 mediators, including TNF-alpha, GM-CSF, and platelet-activating factor, overcomes the adhesion-media

107 The platelet activating factor (PAF) acetyl hydrolase 1b (Pa

108 alyzes the hydrolytic inactivation of plasma platelet activating factor (PAF) and is also known as PA

109 Platelet activating factor (PAF) and PAF-like lipids ind

110 before and after leukocyte stimulation with platelet activating factor (PAF) and PMA.

111 as well as resveratrol and quercetin, on the platelet activating factor (PAF) biosynthetic enzymes, a

112 plexed with the physiological ligand GM2 and platelet activating factor (PAF) have shown binding at t

113 Platelet activating factor (PAF) interacts with cell sur

114 Platelet activating factor (PAF) is a potent inflammator

115 Platelet activating factor (PAF) is a potent lipid autoc

116 tenuate the permeability increase induced by platelet activating factor (PAF) or bradykinin.

117 dministered with either the HIV-1 neurotoxin platelet activating factor (PAF) or the regulatory HIV-1

118 th BN52021, WEB-2170, and WEB-2086 (specific platelet activating factor (PAF) receptor antagonists),

119 Both LPS and BLP stimulated the synthesis of platelet activating factor (PAF), a potent lipid mediato

120 rved that tumor necrosis factor (TNF)-alpha, platelet activating factor (PAF), and lipopolysaccharide

121 rmyl-methionyl-leucyl-phenylalanine (fMLP)), platelet activating factor (PAF), leukotriene B4 (LTB(4)

122 mbination with uridine 5'-diphosphate (UDP), platelet activating factor (PAF), or lysophosphatidic ac

123 incubated in H2O2 (70 micromol/L, 2 hours), platelet activating factor (PAF), prostaglandin E2 (PGE2

124 ion and chemoattraction, Mig potently blocks platelet activating factor (PAF)- and leukotriene B4 (LT

125 A crystal structure of GM2-AP complexed with platelet activating factor (PAF).

126 se, neutrophil activation in the presence of platelet activating factor (PAF).

127 ed for lysophosphatidylcholine (lysoPCh) and platelet activating factor (PAF).

128 Platelet-activating factor (PAF [1-O-alkyl-2-acetyl-sn-g

129 The plasma form of platelet-activating factor (PAF) acetylhydrolase (PAF-AH

130 Human plasma platelet-activating factor (PAF) acetylhydrolase functio

131 low density lipoprotein and comigrates with platelet-activating factor (PAF) acetylhydrolase on KBr

132 The platelet-activating factor (PAF) acetylhydrolase SsE pro

133 the PAFAH1B2 and PAFAH1B3 subunits of type I platelet-activating factor (PAF) acetylhydrolase, a phos

134 UV-induced keratinocyte-derived platelet-activating factor (PAF) activates mast cell mig

135 idized glycerophosphocholines (Ox-GPCs) with platelet-activating factor (PAF) activity produced non-e

136 uction of glycerophosphocholines that act as platelet-activating factor (PAF) agonists.

137 er short-chained phospholipids--inflammatory platelet-activating factor (PAF) and apoptotic oxidative

138 The production of platelet-activating factor (PAF) and PAF-like phospholip

139 genesis and photoimmune suppression, such as platelet-activating factor (PAF) and serotonin (5-HT) re

140 Platelet-activating factor (PAF) and structurally-relate

141 GS4, also blocked phosphorylation of PAFR by platelet-activating factor (PAF) and, unexpectedly, by p

142 Species related to platelet-activating factor (PAF) and/or lyso-phosphatidy

143 Treatment with platelet-activating factor (PAF) antagonists also reduce

144 Over the past few years, the role of platelet-activating factor (PAF) as a potent mediator in

145 We used platelet-activating factor (PAF) as a proinflammatory ag

146 models and human asthmatics have implicated platelet-activating factor (PAF) as an important inflamm

147 r wild-type control as experimental animals, platelet-activating factor (PAF) at 10(-7) m as the test

148 ponses to the inflammatory mediators C5a and platelet-activating factor (PAF) but did not respond to

149 Platelet-activating factor (PAF) causes wheal and flare

150 at cigarette smoking leads to an increase in platelet-activating factor (PAF) content and PAF recepto

151 ured spleen and liver cytokine responses and platelet-activating factor (PAF) content in mice given C

152 -2) regulate surfactant protein-A (SP-A) and platelet-activating factor (PAF) expression, which incre

153 ittle, if any, role in neutrophil priming by platelet-activating factor (PAF) for OpZ-dependent respo

154 Platelet-activating factor (PAF) has been shown to affec

155 at exposure of neutrophils to E-selectin and platelet-activating factor (PAF) in combination induced

156 In the current study, the role of platelet-activating factor (PAF) in combination with tum

157 t studies have implicated the lipid mediator platelet-activating factor (PAF) in UVB-mediated systemi

158 models of LE that the phospholipid mediator platelet-activating factor (PAF) increases in LE and tha

159 Platelet-activating factor (PAF) increases permeability

160 It is known that platelet-activating factor (PAF) induces severe endothel

161 Evidence suggests that platelet-activating factor (PAF) is a mediator in inflam

162 Platelet-activating factor (PAF) is a mediator of inflam

163 Platelet-activating factor (PAF) is a naturally occurrin

164 Platelet-activating factor (PAF) is a phospholipid media

165 Platelet-activating factor (PAF) is a phospholipid with

166 In this study, we demonstrate that platelet-activating factor (PAF) is a potent inducer of

167 Platelet-activating factor (PAF) is a potent lipid media

168 Platelet-activating factor (PAF) is a potent lipid media

169 Platelet-activating factor (PAF) is a potent phospholipi

170 Platelet-activating factor (PAF) is a potent proinflamma

171 Platelet-activating factor (PAF) is a potent proinflamma

172 Platelet-activating factor (PAF) is a potent proinflamma

173 Platelet-activating factor (PAF) is a potent, bioactive

174 Platelet-activating factor (PAF) is a powerful proinflam

175 Platelet-activating factor (PAF) is a proinflammatory ph

176 Because platelet-activating factor (PAF) is a proximal mediator

177 Platelet-activating factor (PAF) is an important mediato

178 The phospholipid platelet-activating factor (PAF) is an important mediato

179 Platelet-activating factor (PAF) is implicated in the ca

180 Because the lipid mediator of inflammation, platelet-activating factor (PAF) is released by UV-irrad

181 Animal models show that the receptor for platelet-activating factor (PAF) is responsible for many

182 Although the lipid mediator platelet-activating factor (PAF) is synthesized in respo

183 Although the lipid mediator platelet-activating factor (PAF) is synthesized in respo

184 Though the lipid mediator platelet-activating factor (PAF) is synthesized in respo

185 Platelet-activating factor (PAF) mediates an array of bi

186 Animal and human data show that platelet-activating factor (PAF) mediates the life-threa

187 ry potential of the proinflammatory mediator platelet-activating factor (PAF) on the subcellular dist

188 urvival after anaphylaxis, administration of platelet-activating factor (PAF) or histamine, and expos

189 th Kindlin-2 siRNA showed enhanced basal and platelet-activating factor (PAF) or lipopolysaccharide-s

190 esulted from inhibitory signals generated by platelet-activating factor (PAF) or oxidized LDL that ac

191 ncreased AA and PGE2 release, accompanied by platelet-activating factor (PAF) production.

192 We hypothesize that platelet-activating factor (PAF) receptor (PAFR) ligatio

193 LAU-0901, a novel platelet-activating factor (PAF) receptor antagonist, is

194 regation was inhibited by antagonists of the platelet-activating factor (PAF) receptor but not inhibi

195 tor and that antagonists of 5-HT(2A) and the platelet-activating factor (PAF) receptor can block cis-

196 f intracellular Leishmania, we surmised that platelet-activating factor (PAF) receptor had a signific

197 Activation of the platelet-activating factor (PAF) receptor leads to a dec

198 onist of the PTX-sensitive G protein-coupled platelet-activating factor (PAF) receptor, blocked the a

199 Corneal stromal myofibroblasts express the platelet-activating factor (PAF) receptor, but its role

200 ba extracts and are known antagonists of the platelet-activating factor (PAF) receptor.

201 Ginkgolides are known antagonists of the platelet-activating factor (PAF) receptor.

202 igated for their ability to bind to a cloned platelet-activating factor (PAF) receptor.

203 These studies examined the role of the platelet-activating factor (PAF) signaling system in UVB

204 Previously, we reported that platelet-activating factor (PAF) stimulates higher G pro

205 ne suppression are the binding of UV-induced platelet-activating factor (PAF) to its receptor and the

206 and the proinflammatory glycerophospholipid platelet-activating factor (PAF) were markedly reduced i

207 cell types with respect to the metabolism of platelet-activating factor (PAF), a biologically active

208 s by exploiting molecular mimicry to degrade platelet-activating factor (PAF), a host-derived inflamm

209 Platelet-activating factor (PAF), a phospholipid second

210 We analyzed the effect of platelet-activating factor (PAF), a potent phospholipid

211 Recent studies suggest that the action of platelet-activating factor (PAF), a potent phospholipid

212 Platelet-activating factor (PAF), a potent phospholipid

213 ated endocytosis (CME), we hypothesized that platelet-activating factor (PAF), an effective chemoattr

214 in corneal epithelial cells stimulated with platelet-activating factor (PAF), and interferes with th

215 as tumor necrosis factor-alpha (TNF-alpha), platelet-activating factor (PAF), and lipopolysaccharide

216 ctively induced by the addition of PGE(2) or platelet-activating factor (PAF), another lipid cytokine

217 UVB radiation generates the lipid mediator, platelet-activating factor (PAF), as well as oxidized ph

218 nergistic signaling induced by serotonin and platelet-activating factor (PAF), but not histamine.

219 Leu-Phe (fMLP), adenosine diphosphate (ADP), platelet-activating factor (PAF), interleukin-8 (IL-8),

220 shown that the lipid inflammatory mediator, platelet-activating factor (PAF), synthesized by activat

221 mbrane inhibits hyperpermeability induced by platelet-activating factor (PAF), VEGF in ECV-CD8eNOSGFP

222 e calcium entry (SOCE) following the initial platelet-activating factor (PAF)-induced release of Ca(2

223 Degrading platelet-activating factor (PAF)-like lipids in L5 by a

224 is mediated, in part, by the lipid mediator platelet-activating factor (PAF).

225 mediators, including adhesion molecules and platelet-activating factor (PAF).

226 rat small intestine and is down-regulated by platelet-activating factor (PAF).

227 P) protects mice from lethal challenges with platelet-activating factor (PAF).

228 rete the inflammatory phospholipid mediator, platelet-activating factor (PAF).

229 phospholipids and the inflammatory mediator platelet-activating factor (PAF).

230 eparations with or without pretreatment with platelet-activating factor (PAF).

231 nvade endothelial cells via the receptor for platelet-activating factor (PAF).

232 secrete the lipid mediator of inflammation, platelet-activating factor (PAF).

233 reduces neutrophil recruitment by targeting platelet-activating factor (PAF).

234 roduction of prostaglandin I(2) (PGI(2)) and platelet-activating factor (PAF).

235 Among the proinflammatory mediators, platelet-activating factor (PAF, 1-O-alkyl-2-acetyl-sn-g

236 -alkyl-2-acetyl-sn-glycero-3-phosphocholine (platelet-activating factor, PAF) and the generation of 2

237 diated responses, RGS4 and the receptors for platelet-activating factor (PAFR), formylated peptides (

238 hown that the protein acts primarily as lyso-platelet-activating factor-phospholipase C.

239 phils were treated with fMLP with or without platelet-activating factor, PMA alone, or tumor necrosis

240 nitiates the biosynthesis of eicosanoids and platelet-activating factor, potent mediators of inflamma

241 Under the same experimental conditions, platelet-activating factor primed neutrophils for supero

242 factor, the ability of alpha-toxin to induce platelet-activating factor production was assessed, and

243 regation was blocked using a monoclonal anti-platelet activating factor receptor (PafR) antibody and

244 ine, an H1R antagonist, blocked EAE, and the platelet activating factor receptor antagonist CV6209 re

245 creased adherence mediated by binding to the platelet activating factor receptor on epithelial cells.

246 d receptor-1, protease activated receptor-3, platelet activating factor receptor, and factor V.

247 D synthase, histamine receptor type 1 (H1R), platelet activating factor receptor, Ig Fc epsilon recep

248 eir ability to generate oxidized lipids with platelet-activating factor receptor (PAF-R) agonist acti

249 by generating oxidized lipid agonists of the platelet-activating factor receptor (PAF-R).

250 er of melanoma metastasis, via activation of platelet-activating factor receptor (PAFR) and cAMP-resp

251 dditional recognition system mediated by the platelet-activating factor receptor (PAFr) and directed

252 e hypothesis that influenza up-regulates the platelet-activating factor receptor (PAFr) and thereby p

253 Inhibitors of platelet-activating factor receptor (PAFR) blocked LTA-

254 We have previously shown that the Platelet-Activating Factor Receptor (PAFR) engagement in

255 The platelet-activating factor receptor (PAFr) has been sugg

256 hibitors identified a prominent role for the platelet-activating factor receptor (PAFr) in hypoxia-as

257 Platelet-activating factor receptor (PAFR) is a G protei

258 Platelet-activating factor receptor (PAFr) mediates pneu

259 f synaptic activity in a manner dependent on platelet-activating factor receptor (PAFR) signaling.

260 polymeric immunoglobulin receptor (pIgR) and platelet-activating factor receptor (PAFr) to attach and

261 iciency in interleukin 1alpha (IL-1alpha) or platelet-activating factor receptor (PAFR), an important

262 of A. baumannii binds to A549 cells through platelet-activating factor receptor (PAFR), resulting in

263 Moreover, expression of platelet-activating factor receptor (PAFR), which is kno

264 nvolved in immune responses include CD36 and platelet-activating factor receptor (PAFR).

265 r airway cells is mediated by host-expressed platelet-activating factor receptor (PAFR).

266 oupled receptors and excluded key candidates platelet-activating factor receptor and CCR5.

267 experiments revealed that L5 signals through platelet-activating factor receptor and lectin-like oxid

268 s demonstrate the differential expression of platelet-activating factor receptor and TLR-4 in uterine

269 nti-eotaxin and anti-RANTES mAbs, but not by platelet-activating factor receptor antagonists (CV6209,

270 s NK(2), calcitonin gene-related peptide, or platelet-activating factor receptor antagonists had no e

271 Pretreatment of HaCaT cells with platelet-activating factor receptor antagonists, or over

272 Platelet-activating factor receptor blockade protected s

273 tion was assessed, and whether the epidermal platelet-activating factor receptor could augment toxin-

274 ctive effect resulted in part from decreased platelet-activating factor receptor expression on endoth

275 antibody or therapeutic agents that modulate platelet-activating factor receptor expression, may conf

276 stry studies demonstrate the presence of the platelet-activating factor receptor in both endometrial

277 nally, retroviral-mediated expression of the platelet-activating factor receptor into the platelet-ac

278 Anaphylaxis was inhibited by platelet-activating factor receptor or histamine recepto

279 milar involvement for an unrelated GPCR (the platelet-activating factor receptor), indicating that it

280 Bacterial lipoteichoic acid activates the platelet-activating factor receptor, which is G protein-

281 rom the international phase III trial of the platelet-activating factor receptor-antagonist Lexipafan

282 platelet-activating factor receptor into the platelet-activating factor receptor-negative epithelial

283 ent studies used model systems consisting of platelet-activating factor receptor-positive and -negati

284 lin receptor, or cell wall phosphorylcholine/platelet-activating factor receptor.

285 signaling can be augmented via the epidermal platelet-activating factor receptor.

286 holine residues on pneumococcal cell wall to platelet-activating factor receptor.

287 holine (ChoP), a ligand for the receptor for platelet-activating factor (rPAF).

288 ity, we found that histamine, serotonin, and platelet-activating factor, small molecule vascular perm

289 hil, macrophage, and neutrophil secretion of platelet-activating factor subsequent to FcgammaR stimul

290 of PMN cationic entry after thapsigargin or platelet-activating factor suggested that SOCE occurs th

291 lus for the synthesis for the lipid mediator platelet-activating factor, the ability of alpha-toxin t

292 Depletion of basophils and blockade of platelet-activating factor, the key components of the Ig

293 ructurally diverse neutrophil-priming agents platelet-activating factor, TNF-alpha, and the substance

294 rotein is rapidly synthesized in response to platelet activating factor under the control of a specia

295 Lysophosphatidylcholine and lyso-platelet-activating factor were also associated directly

296 nt chemicals (bradykinin, capsaicin, low pH, platelet-activating factor), whereas Adelta-fibres are r

297 5-hydroxytryptamine), platelet factor 4, and platelet-activating factor, which specifically stimulate

298 lpha-toxin resulted in significant levels of platelet-activating factor, which were approximately 50%

299 l, lipid mediators lysophosphatidic acid and platelet-activating factor, whose signals are implicated

300 The first phase is triggered by platelet-activating factor within minutes, but needs the